The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Advice for approaching TP53-mutated AML in community settings
Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly discusses how to approach TP53-mutated acute myeloid leukemia (AML) in community settings, highlighting the value of enrolling patients in clinical trials with the end goal of stem cell transplant. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
